Literature DB >> 8776749

Expression and purification of recombinant, glycosylated human interferon alpha 2b in murine myeloma NSo cells.

C Rossmann1, N Sharp, G Allen, D Gewert.   

Abstract

We have expressed recombinant human interferon-alpha 2b in mammalian cells and isolated cell lines constitutively secreting very high levels of biologically active protein. The expression system takes advantage of the strong human cytomegalovirus immediate early promoter in mouse myeloma NSo cells and glutamine synthetase as a selectable marker; spontaneous mutants with amplified gene copy numbers were selected by growth of primary transfectants in the presence of methionine sulfoximine. Using this procedure, we have isolated a recombinant NSo cell line which secretes human interferon at the rate of 20 micrograms/10(6) cells/24 h and accumulates up to 120 micrograms/ml (approximately 2.4 x 10(7) U/ml) following prolonged undiluted culture. The interferon (IFN) could be efficiently purified on a polyclonal bovine anti-human IFN alpha specific antibody column and the glycosylation pattern was found to be similar to that of nonrecombinant IFN alpha 2b purified from virus-induced human Namalwa cells. The biological activity of the recombinant material was indistinguishable from that of natural IFN from Namalwa cells, and the specific antiviral activity, as assayed on human HeLa cells challenged with encephalomyocarditis virus, was 2 x 10(8) IU/mg, similar to that of nonrecombinant IFN preparations. This represents the highest reported level of glycosylated, recombinant IFN expression in a stable mammalian system and is a significant advance in the large-scale production of these clinically important cytokines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8776749     DOI: 10.1006/prep.1996.0050

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  7 in total

1.  Expression of biologically active human interferon alpha 2b in the milk of transgenic mice.

Authors:  Hui Li; Qingyou Liu; Kuiqing Cui; Jinfeng Liu; Yanping Ren; Deshun Shi
Journal:  Transgenic Res       Date:  2012-06-03       Impact factor: 2.788

2.  Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody.

Authors:  Aviva Joseph; Jian Hua Zheng; Ken Chen; Monica Dutta; Cindy Chen; Gabriela Stiegler; Renate Kunert; Antonia Follenzi; Harris Goldstein
Journal:  J Virol       Date:  2010-04-21       Impact factor: 5.103

3.  Advances in animal cell recombinant protein production: GS-NS0 expression system.

Authors:  L M Barnes; C M Bentley; A J Dickson
Journal:  Cytotechnology       Date:  2000-02       Impact factor: 2.058

4.  Establishment of a stable CHO cell line with high level expression of recombinant porcine IFN-β.

Authors:  Weiye Chen; Wenyan Cao; Huijun Zhao; Qianqian Hu; Linmao Qu; Sen Hu; Jinying Ge; Zhiyuan Wen; Xijun Wang; Haobo Li; Kehe Huang; Zhigao Bu
Journal:  Cytokine       Date:  2011-04-01       Impact factor: 3.861

5.  Heterologous expression, immunochemical and computational analysis of recombinant human interferon alpha 2b.

Authors:  Iram Gull; Zahoor Qadir Samra; Muhammad Shahbaz Aslam; Muhammad Amin Athar
Journal:  Springerplus       Date:  2013-06-15

6.  Stable high volumetric production of glycosylated human recombinant IFNalpha2b in HEK293 cells.

Authors:  Martin Loignon; Sylvie Perret; John Kelly; Denise Boulais; Brian Cass; Louis Bisson; Fatemeh Afkhamizarreh; Yves Durocher
Journal:  BMC Biotechnol       Date:  2008-08-27       Impact factor: 2.563

7.  Enabling low cost biopharmaceuticals: high level interferon alpha-2b production in Trichoderma reesei.

Authors:  Christopher P Landowski; Eero Mustalahti; Ramon Wahl; Laurence Croute; Dhinakaran Sivasiddarthan; Ann Westerholm-Parvinen; Benjamin Sommer; Christian Ostermeier; Bernhard Helk; Juhani Saarinen; Markku Saloheimo
Journal:  Microb Cell Fact       Date:  2016-06-10       Impact factor: 5.328

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.